Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antihypertensive drugs
Biotech
AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win
The phase 3 win for baxdrostat boost AstraZeneca's attempts to turn the molecule’s long half-life into a competitive advantage.
Nick Paul Taylor
Oct 7, 2025 4:01am
Novo vs. KBP Chapter 2: 'Anomalous' trial results
Oct 2, 2025 3:00am
With no Tryvio buyer, Idorsia recoups $100M from Viatris deal
Feb 26, 2025 7:00am
J&J hands back $230M blood pressure drug with approval in sight
Sep 6, 2023 6:20am
Mineralys upsizes IPO to raise $192M for race with AstraZeneca
Feb 10, 2023 9:10am
Quantum's high-stakes hypertension phase 3 fails, tanking stock
Oct 28, 2022 8:55am
